Reckitt Benckiser is doubling its spend on OTC drug research and development as it looks to turn around this ailing part of its Health business.
Speaking as the UK-based health and hygiene player reported OTC sales down 3% in 2020, CFO Jeff Carr said RB was already seeing signs of positive returns on its increased R&D investment with new product launches such as Nurofen Long Lasting 12-hour release ibuprofen
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?